Risk of cardiovascular complications related to blood glucose concentration: from diabetes to prediabetes

Czech version

Authors: Michael Jenšovský ¹; Jana Malinovská ¹; Ludmila Brunerová ²; Veronika Vejtasová ³; Rhea Saldanha ¹; Kristýna Kučera ⁴; Jan Brož ¹
Authors‘ workplace: Interní klinika 2. LF UK a FN Motol, Praha ¹; Diabetologické centrum II. interní kliniky 3. LF UK a FN Královské Vinohrady, Praha ²; Kardiologická klinika 2. LF UK a FN Motol ³; Arbeitsgemeinschaft der Belegärzte am Alice-Hospital, Darmstadt, Germany ⁴
Published in: Vnitř Lék 2020; 66(7): 20-25
Category:

Overview

Diabetes is an established risk factor of cardiovascular disease including the coronary heart disease (CHD) and elevates the risk of cardiovascular death 2 times. Based on current evidence the risk of acquiring the CHD increases accordingly to the level of fasting blood glucose even in the prediabetic range. In the range of 5.6–6.0mmol/l the risk is 1.11, in the range of 6.1–6.9mmol/l the risk is 1.17. In the range of HbA1c of 42–47mmol/l the risk of the CHD is 1.28. The probability of the CHD occurrence therefore does indeed increase in conjunction with the fasting blood glucose levels but the dependence is not linear.

Keywords:

blood glucose concentration – cardiovascular disease – diabetes mellitus – prediabetes

Sources

1. Qazi MU, Malik S. Diabetes and Cardiovascular Disease: Insights from the Framingham Heart Study. Glob Heart 2013; 8: 43–48.

2. Low Wang CC, Hess CN, Hiatt WR, et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation 2016; 133: 2459–2502.

3. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13.

4. Gregg EW, Li Y, Wang J, et al. Changes in Diabetes-Related Complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514–1523.

5. Roglic G. Global report on diabetes. Geneva, Switzerland: World Health Organization 2016.

6. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339: 229–234.

7. Whiteley L, Padmanabhan S, Hole D, et al. Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care 2005; 28: 1588–1593.

8. Di Angelantonio E, Kaptoge S, Worrmser D, et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52–60.

9. Škrha J. Kardiovaskulární mortalita u diabetu. Vnitř Lék 2017; 63: 447–449.

10. Gregg EW, Li Y, Wang J, et al. Changes in Diabetes-Related Complications in the United States, 1990–2010. N Engl J Med 2014; 370: 1514–1523.

11. Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med 2017; 376: 1407–1418.

12. Brož J, Honěk P, Dušek L, et al. The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average. Vnitř Lék 2015; 61(Suppl. 3): 14–20.

13. Perušičová J, Pelikánová T, Škrha J, et al. Doporučený postup péče o nemocné s prediabetem. DMEV 2012; 15: 20–22.

14. Rett K, Gottwald-Hostalek U. Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. Curr Med Res Opin 2019; 35: 1529–1534.

15. Chatterton H, Younger T, Fischer A, et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 2012; 345: e4624–e4624.

16. Buysschaert M, Medina JL, Buysschaert B, et al. Definitions (and Current Controversies) of Diabetes and Prediabetes. Current Diabetes Reviews 2015; 12: 8–13.

17. Tabak AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379: 2279–2290.

18. Tabak AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215–2221.

19. International Diabetes Federation. IDF Diabetes Atlas. 2017 (Online) 8th ed. International Diabetes Federation: Brussels, Belgium 2017.

20. Žejglicová K, Kratěnová J, Lustigová M, et al. Vybrané ukazatele zdravotního stavu české populace – výsledky studie EHES. Prakt Lek 2017; 97: 123–130.

21. Čapková N, Lustigová M, Kratěnová J, et al. Vybrané ukazatele zdravotního stavu české populace – Studie EHES 2014. Hygiena 2017; 62: 35–37.

22. Lustigová M, Čapková N. Prevalence rizikových faktorů srdečně-cévních onemocnění v Česku z pohledu demografických charakteristik – vybrané výsledky studie EHES. Demografie 2017; 59: 162–169.

23. Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circulation Research 2018; 122: 1135–1150.

24. Stengård JH, Tuomilehto J, Pekkanen J, et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: The Finnish cohorts of the seven countries study. Diabetologia 1992; 35: 760–765.

25. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–2222.

26. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2006; 28: 88–136.

27. Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. Diabetes Care 2017; 41: 104–111.

28. Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all-cause mortality: systematic review and meta-analysis. BMJ 2016; 355: i5953.

29. Açar B, Ozeke O, Karakurt M, et al. Association of Prediabetes With Higher Coronary Atherosclerotic Burden Among Patients With First Diagnosed Acute Coronary Syndrome. Angiology 2018; 70: 174–180.

30. Vistisen D, Kivimäki M, Perreault L, et al. Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study. Diabetologia 2019; 62: 1385–1390.

31. Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes & Endocrinology 2019; 7: 452–461.

32. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020; 41: 566–570.

33. Armato JP, Defronzo RA, Abdul-Ghani M, et al. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). The Lancet Diabetes and Endocrinology 2018; 6: 781–789.

34. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes – 2019. Diabetes Care 2019; 42(Suppl. 1): S29–S33.

35. Shaw JE Prediabetes: lifestyle, pharmacotherapy or regulation? Therapeutic Advances in Endocrinology and Metabolism 2019; 10: 128–133.